leadf
logo-loader
viewAntisense Therapeutics Ltd
(
ASX:ANP
)

Full interview: Antisense Therapeutics further develops therapeutic for Duchenne Muscular Dystrophy with ATL1102

Antisense Therapeutics Limited (ASX:ANP) managing director Mark Diamond updates Proactive on the company’s progress in developing a therapeutic for a severe disease called Duchenne Muscular Dystrophy, or DMD.

The managing director spoke about the importance of the drug ATL1102 that is being progressed through the company’s Phase 2 trial, saying it has shown significant success.

Diamond says some important regulatory interactions necessary for efficient and timely advancement to the next stage of development of ATL1102 are underway.

Quick facts: Antisense Therapeutics Ltd

Follow
ASX:ANP

Price: 0.175 AUD

Market Cap: $100.53 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

4 hours, 17 minutes ago

2 min read